vascular endothelial growth factor-C; platelet-derived growth factor-BB; lymphangiogenesis; capillary stabilization THE DEVELOPMENT OF TECHNOLOGIES that can rescue ischemic organs will have a great impact on physicians, because the rapid increase in the number of patients with lifestyle-related diseases, including atherosclerosis, diabetes, and metabolic syndrome, is a significant factor in the dramatically increasing incidence of peripheral arterial disease and ischemic heart disease. The goal of "therapeutic neovascularization" is to supply a sufficient blood flow to ischemic tissue that is intractable using the currently available therapeutics (medication, catheter intervention, and bypass surgery) (4) . However, recent clinical studies of therapeutic neovascularization using angiogenic factor proteins or genes showed limited efficacy in double-blind multicenter trials (6, 7) . Since a number of experimental studies from laboratories all over the world have shown the promise of therapeutic neovascularization, more research and clinical assessments are needed to reach success in this field.
Identification of the optimized conditions for therapeutic neovascularization, including the choice of angiogenic factors and their required expression levels, will undoubtedly contribute to the understanding of the molecular and cellular mechanisms of "physiological" angiogenesis accompanying sufficient tissue circulation. Toward that end, we used murine models of severe hindlimb ischemia to extensively study the limb-salvaging effect of the gene transfer of various combinations of angiogenic factors, including vascular endothelial growth factor A (VEGF 165 ), fibroblast growth factor (FGF)-1 and -2, angiopoietin-1 and -2, and hepatocyte growth factor and vectors (17, 20, 26, 28 , and unpublished data). Notably, the strong boost of FGF-2 using recombinant Sendai virus (SeV) showed representative and highly efficient limb salvaging effects. Moreover, it was interesting that the therapeutic effect of FGF-2 was highly dependent on the endogenously upregulated VEGF and hepatocyte growth factor via the autocrine mode of action of the platelet-derived growth factor (PDGF)-AA/PDGF-␣-receptor (PDGFR-␣)/p70 S6K signal transduction pathway in mural/mesenchymal cells (MCs) (20, 26) . Also noteworthy is that we recently demonstrated that the autocrine system of PDGF-AA/ PDGFR-␣/p70 S6K in malignancies was more closely related to the size and prognosis of lung cancers than VEGF itself (24) , suggesting that this signal may be a ubiquitous system determining the proangiogenic property of physiological and pathological angiogenesis.
In addition to the biological activity of FGF-2 in angiogenenic process, FGF-2 has also been reported to exert lymphangiogenesis, unlike the case with VEGF-A, via direct induction of a typical lymphangiogenic factor, VEGF-C (13) . Although there are some conflicts regarding the role of VEGF-A in the formation of lymphatics (2, 5) , lymphangiogenesis is known to be essential for the control of extracellular fluid and tissue, suggesting the necessity of lymphangiogenesis during therapeutic neovascularization.
On the other hand, there is little information on whether angiogenesis and lymphangiogenesis are independent of each other or not. It has been believed that type 3 VEGF receptor (VEGFR3, also known as fms-like tyrosine kinase-4: FLT-4) is expressed dominantly on lymphatic endothelial cells (ECs) (11) . However, some studies have suggested that VEGFR3/ FLT-4 is expressed not only on lymphatic ECs, but also on quiescent and proliferating capillary ECs (21, 30) , suggesting that the VEGF-C/VEGFR3 system has complex biological properties in angiogenesis. However, there is no direct information indicating the precise biological role of VEGF-C/ FLT-4 during angiogenesis.
Therefore, we here investigated the role of the VEGF-C/ VEGFR3 system during FGF-2-mediated therapeutic neovascularization using AFL-4, a murine VEGFR3-specific neutralizing antibody (12, 13) . We here report direct evidence that VEGF-C/ VEGFR3 contributed to capillary integrity in a PDGF-BB/ PDGFR-␤-dependent fashion in murine models of therapeutic neovascularization; that is, a paracrine loop may exist between between ECs and MCs, contributing to the representative efficacy of FGF-2 to treat severe hindlimb ischemia.
MATERIALS AND METHODS

Animals and Recombinant SeV
Male C57BL/6J (6-wk-old) mice and Balb/c nu/nu (5-wk-old) mice (purchased from KBT Oriental, Charles River Grade, Tosu, Saga, Japan) were used for the limb salvage model and the autoamputation model, respectively (17, 20, 26, 28) . The surgical procedures to induce severe hindlimb ischemia or gene transfer were described in detail previously, and the limb amputation was categorized as 4 scores for evaluation of therapeutic effects of gene transfer [Limb Salvage Score (LSS)]: LSS ϭ 4, complete limb salvage; LSS ϭ 3, limb necrosis below heel; LSS ϭ 2, limb necrosis below knee; LSS ϭ 1, limb necrosis above knee; and LSS ϭ 0, total autoamputation around the inguinal ligament (17, 20, 26, 28) . All animal experiments were done according to protocols approved by the Institutional Committee for Animal Experiments and by the Institutional Committee for Recombinant DNA and Infectious Pathogen Experiments, Kyushu University. These experiments were done in accordance with recommendations for the proper care and use of laboratory animals and according to The Law (No. 105) and Notification (No. 6) of the Japanese Government. F-defective nontransmissible recombinant SeVs expressing human FGF-2 (hFGF-2) or firefly luciferase were prepared and titrated, as previously described (14) .
Antibodies
A monoclonal antibody neutralizing murine VEGFR3/FLT-4 (AFL-4) was purified from culture medium of rat hybridoma AFL-4 (IgG 2ak), as previously described (12) . Goat anti-PDGF-BB neutralizing antibody was purchased from R&D Systems (Minneapolis, MN). These antibodies were administered in vivo, as presented in Figs. 1 and 6. For continuous injection of AFL-4, a disposable microosmotic pump (model 1007D, ALZA, Mountain View, CA) was used, as previously described (17, 20, 26, 28) . Goat anti-PDGFR-␣ and anti-PDGFR-␤ neutralizing antibodies for in vitro experiments were purchased from R&D Systems. Anti-human VEGF-C goat polyclonal antibody (R&D Systems) was used for Western blotting. Anti-murine lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1) rabbit polyclonal antibody was generated in our laboratory (18) . Anti-platelet-EC adhesion molecule (PECAM)-1 rabbit monoclonal antibody was purchased from BD Pharmingen (Franklin Lakes, NJ). Each isotype-matched antibody was used in control experiments.
Cells and Reagents
Human aortic smooth muscle cells (Kurabo, Tokyo, Japan) and human fetal lung fibroblast (MRC5; American Type Culture Collection) were purchased. Bovine aortic smooth muscle cells (BSMCs), capillary ECs from bovine retina (BCEs), and human umbilical vein ECs (HUVECs) were isolated as previously described (20, 28) . These cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, and used within six passages.
Laser Doppler Perfusion Image
The ischemic (left)-to-normal (right) limb blood flow ratio was measured by a laser Doppler perfusion image (LDPI) analyzer (Moor Instruments, Devon, UK) (17, 20, 26, 28) . To minimize data variables due to ambient light and temperature, the LDPI index was expressed as the ratio of left (ischemic) to right (nonischemic) limb blood flow.
Histological Analysis and Immunohistochemistry
After the LDPI analysis, left ischemic thigh muscles from C57BL/ 6/J limb salvage model mice were sectioned at midportion as frozen samples and then were subjected as hematoxylin and eosin stained samples to computer-assisted quantification of the areas of the histological categories, muscle necrosis without repair response, granulation tissue, muscle regeneration, and undamaged muscles (17) , using MacScope software. The lymphatic or blood vessel density of each area of thigh muscle was immunohistochemically determined in serial sections, using anti-LYVE-1 antibody and anti-PECAM-1 antibody. The immunohistochemical procedure was described previously (18) . The lymphatic vessels were identified as LYVE-1-positive vessels that showed brown, morphologically circumferential products of one or more ECs with counterstaining. The total numbers of lymphatic vessels in 10 randomly selected fields of undamaged tissue were counted under a light microscope at high-power magnification (ϫ200). The blood vessels were identified as PECAM-1-positive and LYVE-1-negative vessels, labeled by double immunohistochemistry (1), and showed brown, morphologically circumferential products of one or more ECs with counterstaining (Supplemental Fig. I ; the online version of this article contains supplemental data). The total number of blood vessels was counted under a light microscope at high-power magnification (ϫ200) in regenerative and granulation tissue. The vessel density in each area was expressed as the number of vessels per millimeter squared. These histological findings were evaluated by double-blind examiners (Y. Yonemitsu and T. Nakano).
Semithin Sectioning and Electron Microscopic Study
Whole thigh muscles from 10 animals (5 for FGF-2 ϩ AFL-4 and 5 for FGF-2 ϩ control IgG) were cut into 2-mm cubes (at least 10 specimens per animal) and rinsed in 0.1 M cacodylate buffer (CacoB). The specimens were then prefixed with 4% glutaraldehyde in 0.1 M CacoB. After rinsing, the cells were postfixed for 90 min with 1% osmium tetroxide in 0.1 M CacoB, dehydrated through a graded ethanol series, stained en bloc during dehydration with a saturated solution of uranyl acetate in 70% ethanol, and embedded in Epon. Semithin (1 m) sections were stained with Azure II and examined under a light microscope. Undamaged muscle tissues were picked up for further examination; at least three blocks were obtained from each animal. Ultrathin (60 nm) sections were cut from blocks and mounted on copper grids. The sections were stained with lead citrate and uranyl acetate and examined under a JEM1200 electron microscope (JEOL, Tokyo, Japan).
Enzyme-linked Immunosorbent Assay
Protein contents in culture medium or human serum were determined using Quantikine Immunoassay systems for human PDGF-BB (R&D Systems) and the VEGF-C enzyme-linked immunosorbent assay (ELISA) kit (Zymed Laboratories, South San Francisco, CA), according to the manufacturer's instructions. Although there was no detail regarding detectable forms of VEGF-C processing variations in the ELISA instructions, we confirmed that this system is available only for the secreted form of VEGF-C, not for the mature form (see Fig. 3A ). Regarding ELISA data analysis, target protein content in culture medium was expressed as the amount of protein secreted from 10,000 cells for 24 h.
Semiquantitative RT-PCR and Real-time RT-PCR
Total RNA extraction and cDNA synthesis. Total cellular RNA was extracted from culture cells or murine thigh muscles by the ISOGEN system (Wako Pure Chemical Industries, Osaka, Japan), according to the manufacturer's instructions, and was also treated with RNase-free DNase I (Boehringer-Mannheim Biochemical, Mannheim, Germany). Subsequently, 25 ng of total RNA were reverse transcribed and subjected to PCR.
Semiquantitative RT-PCR. Semiquantitative amplification of target genes was done in a T-gradient thermal cycler (Biometra, Gottingen, Germany). PCR products were electrophoresed and were visualized by ethidium bromide staining. The oligonucleotide sequence of PCR primers and the PCR conditions are listed in Supplemental Table I .
Real-time PCR. Real-time monitoring of the amplification of target genes and quantification of gene expression levels were done by a Sequence Detection System, model 7000 (Applied Biosystems, Tokyo, Japan), according to the manufacturer's instructions for TaqMan methods (20, 28) . The oligonucleotide sequences of PCR primers and TaqMan probes are listed in Supplemental Table II. The expression level of the target genes was standardized by the GAPDH level in each sample and was expressed as a fold increase over the control level.
Northern Blotting
Thirty micrograms of total cellular RNA, isolated using the ISOGEN system, were electrophoresed and transferred onto a nylon membrane. The filters were hybridized overnight at 60°C with random [␣-
32 P]dCTP-labeled probes obtained from full-length human VEGF-C cDNA that was cloned in our laboratory. The bands were then visualized and subjected to densitometry using a BAS 2500 BioImage Analyzer (Fuji Photo Film, Tokyo, Japan).
Western Blot Analysis
The culture medium was concentrated using the Microcone YM-30 system (Millipore, Bedford, MA). To eliminate proteins nonspecifically binding to the beads and goat IgG, serum was preexposed to the nonimmune goat IgG binding beads. These samples were separated on SDS-PAGE under reducing conditions and were transferred to the polyvinylidene fluoride membrane. An hour after treatment of blocking with PBS containing 5% nonfat milk, the membrane was incubated overnight with primary antibody solution (200 ng/ml primary antibody in 5% BSA and 0.1% Tween 20 in PBS) at 4°C and was then treated for 2 h with Envision for goat IgG (DAKO, Glostrup, Denmark) at room temperature. VEGF-C was visualized by chemoluminescence (Cell Signaling Technology, Beverly, MA).
Statistical Analysis
All data were expressed as means Ϯ SE and were analyzed by one-way ANOVA with Fisher's adjustment. The statistical significance of the survival experiments was determined using the log-rank test, and P Ͻ 0.05 was considered statistically significant.
RESULTS
VEGFR3/FLT-4 Signaling Is Essential During FGF-2-mediated Therapeutic Neovascularization
To identify the potential role of VEGFR3/FLT-4 in FGF-2-mediated therapeutic neovascularization, we first examined the effect of AFL-4, a monoclonal antibody against murine VEGFR3/ FLT-4, which disrupts the interaction between VEGF-C/-D and VEGFR3/FLT-4, on a therapeutic model against autoamputation due to severe hindlimb ischemia in Balb/c nu/nu mice (17, 20, 26, 28) . A recombinant SeV-mediated (16, 17, 20, 23, 26, 28, 31, 32) boost of hFGF-2 (SeV/dF-hFGF-2) protected the autoamputation, compared with a control vector expressing reporter gene luciferase (SeV-luciferase), and the effect was diminished by neutralization of VEGFR3/FLT-4 activity (Fig. 1A) .
In a C57BL6/J limb salvage model, which used a rare limb amputation due to the surgical procedure described previously (17, 20, 26, 28) , administration of AFL-4 to SeV/dF-hFGF2-treated mice resulted in amputation in ϳ60% of the experimental animals, although the control animals did not lose their limbs (Fig. 1B) .
We then examined the blood flow of ischemic hindlimb using a laser Doppler flow image analyzer. As shown in Fig.  1C , administration of AFL-4 markedly diminished the increase of blood flow in severely ischemic hindlimbs treated with FGF-2; the level was far lower than that seen in control mice. Interestingly, inhibition of VEGFR3/FLT-4 activity in vivo led to swelling, not only of the ischemic hindlimb, but also of the scrotum during the experimental course (Fig. 1D) .
These results indicated that VEGFR3/FLT-4 is crucial to the benefit of FGF-2-mediated therapeutic neovascularization.
Inhibition of VEGFR3/FLT-4 Activity in Ischemic Limb Abrogates Lymphangiogenesis, But Not Angiogenesis, Whereas That Leads to the Disruption of Capillary Integrity
To assess the possible mechanism underlying the effect of AFL-4 on FGF-2-mediated therapeutic neovascularization, we next examined angiogenesis and lymphangiogenesis 10 days after the induction of ischemia in a C57BL6J limb salvage model.
We first assessed the effects of FGF-2 and AFL-4 on tissue conditions of ischemic whole thigh muscles, categorized into four distinct areas, as described in our laboratory's previous study (undamaged: histologically normal muscles; regenerating: regenerating muscles showing frequent fusion of multinuclear muscle cells; granulation: granulation tissue showing mononuclear cell infiltration and proliferation of fibroblasts/ myofibroblasts; and necrotic: necrotic muscles without regenerating muscle cells) (17) . Typical histological findings are shown in Fig. 2A , left four panels. As shown in Fig. 2A , right, FGF-2 gene transfer strongly contributed to the reduction of the necrotic area and to the increase of undamaged and regenerating areas. In turn, administration of AFL-4 resulted in the decrease of undamaged muscle area and the increase of necrotic and granulation areas, possibly reflecting the results of Fig. 1 .
Next, we immunohistochemically examined the extent of lymphangiogenesis (labeled by LYVE-1) and of angiogenesis (labeled by PECAM-1, but not by LYVE-1) in each area, except for the necrotic area. We here used PECAM-1 ϩ / LYVE-1 Ϫ for markers of angiogenesis (blood vessels), because these markers had some doubly positive vessels that were difficult to distinguish from lymphatics (Supplemental Fig. I ). These findings were compatible with similar data from other laboratories (21, 30) .
As shown in Fig. 2B , FGF-2-mediated lymphangiogenesis was seen dominantly in regenerative muscle and in granulation tissue; interestingly, angiogenesis occurred mainly in undamaged muscles, occurred to a lesser extent in regenerative areas, and was rarely seen in granulation tissue. In contrast, inactivation of VEGFR3/FLT-4 via AFL-4 completely abolished lymphangiogenesis, with no significant effect on the number of blood vessels.
When we undertook this examination, we expected these results based on the data obtained in a corneal angiogenesis assay reported by another laboratory (9) . However, a subsequent ultrastructural examination revealed an interesting and unexpected finding of "microaneurysm-like dilatation" of capillary blood vessels in regenerative to undamaged areas. Eponembedded and Azure II-stained thick sections showed apparently dilated blood vessels (Ͼ30 m) in the interstitial spaces of FGF-2/AFL-4-treated ischemic muscles (1-8% of microvessels in each of five sections examined on day 10; Fig.  2C , top right, arrows), while muscles with FGF-2/IgG did not demonstrate a similar pathology at all (Fig. 2C, top left,  arrows) . To avoid the overestimation that would result from the inclusion of dilated lymphatics, we examined only vessels ϩ /LYVE-1 Ϫ by double staining) in ischemic muscles labeled by immunohistochemistry. Vessels showing brown, morphologically circumferential products of one or more endothelial cells (ECs) were counted under a light microscope at high-power magnification (ϫ200) in undamaged, regenerative, and granulation tissue. The vessel density in each area was expressed as the number of vessels per millimeter squared. Occasional PECAM-1 ϩ /LYVE-1 ϩ doubly positive vessels were excluded in this quantification. Note that the administration of AFL-4 completely abolished lymphangiogenesis, but did not affect angiogenesis. Values are means Ϯ SE. *P Ͻ 0.01. C: representative structural abnormality of capillary vessels following AFL-4 administration. Five animals per group were subjected to induced ischemia immediately followed by FGF-2 gene transfer. AFL-4 or control IgG was administered, as indicated by the protocol in Fig. 1 . Ten days later, whole thigh muscles were mounted in Epon, and semithin sections with Azure II staining (top two panels), or ultrathin sections (bottom panel) were prepared for light microscopy or transmission electron microscopy, respectively. Capillaries in undamaged muscles treated with FGF-2 ϩ nonimmune IgG showed normal structure (ϳ10 m in diameter, top left, arrows); however, markedly dilated capillary vessels, over 30 m in diameter and containing some red blood cells (RBCs) similar to microaneurysms, were occasionally found in undamaged muscles with FGF-2 ϩ AFL-4 (top right, surrounded by arrows). Transmission electron microscopy revealed that these abnormal capillaries were each lined with a layer of one to a few ECs frequently showing detachment of mural cells (bottom, arrowhead). m, Muscle fiber; NS, nonsignificant. Scale bar: top two panels ϭ 100 m; bottom panel ϭ 10 m. containing two or more red blood cells, as shown in Fig. 2C . Transmission electron microscopic examination revealed that these dilated capillaries were circumscribed by two or more ECs (Fig. 2C, bottom, arrows) and occasionally showed detached pericytes (Fig. 2C, bottom, arrowhead) .
To confirm that blockade of VEGFR3 activity by AFL-4 might abrogate capillary maturation, we further assessed the ratio of capillary vessels (labeled by PECAM-1) associated with pericyte (labeled by ␣-smooth muscle actin) in areas of regeneration and granulation by double immunohistochemis-try. As shown in Supplemental Fig. II, AFL-4 reduced the ratio of pericyte-covered capillaries in granulation area, but not in regenerating area, indicating that VEGFR3 activity contributed to the maturation of capillary vessels during FGF-2-mediated therapeutic angiogenesis.
These results suggested that VEGFR3 is crucial, not only in lymphangiogenesis, but also in capillary stabilization.
Exogenous Expression of FGF-2 Resulted in the Upregulation of Lymphangiogenesis-related Factors in Murine Ischemic Limbs
To identify the possible molecular mechanisms underlying the FGF-2/lymphangiogenesis axis, we next examined the time course of lymphangiogenesis-related factors following induced hindlimb ischemia and FGF-2 gene transfer.
Real-time quantitative RT-PCR revealed that a dramatic boost of FGF-2 on days 1-3 after SeV-mediated gene transfer (Fig. 3A,  left) , a finding similar to the time course of its protein presented in our laboratory's previous studies (17, 20, 26, 28) . As expected from those studies, the expression pattern of mVEGF-A mRNA was similar to the assessed time course of mVEGF-A protein. On the other hand, the peak expression of mVEGF-C and that of its receptor mVEGFR3/flt-4 was found only in the later phase (around day 7). In contrast, FGF-2 did affect the expression of an alternative lymphangiogenic factor, mVEGF-D (Fig. 3A, left) .
Additionally, we examined the mRNA expression of mPDGF-B, a well-known critical regulator of vascular integrity (8, 15) . Interestingly, the peak expression was detected at day 7 (Fig. 3A) , corresponding to the pattern of VEGF-C mRNA, but not to that of VEGF-A, after a boost of FGF-2.
To identify the cellular mechanism underlying the FGF-2/ VEGF-C/PDGF-BB axis, we performed in vitro studies using two independent ECs [HUVECs and BCEs from retina] and non-EC MCs (NEMCs, MRC5: human fetal lung fibroblast cell line, and BSMCs). These two ECs were comfirmed to express flt-3 mRNA (Supplemental Fig. III) .
In our first assessments, we evaluated the basal expression of ligands/receptors related to the FGF-2/VEGF-C/PDGF-B axis in these cells. RT-PCR revealed that these cells expressed FGFR1, as well as VEGF-C; in contrast, VEGFR2/flk-1, VEGFR3/flt-4, and PDGF-B were detected only in the two ECs, and PDGFR-␤ was found only in the two NEMCs (data not shown). Western blot analyses using anti-human VEGF-C antibody revealed that the corresponding band from the culture medium of human cells (HUVEC and MRC5) was ϳ29 kDa, indicating that VEGF-C released from these cells was in the secreted form and not the mature form (see Fig.  3B ) (9) .
Next, we assessed the effects of hypoxia (2% O 2 ) and FGF-2 on VEGF-C expression. As expected, 24-h culture under hypoxic conditions and FGF-2 supplementation together significantly upregulated the expression of VEGF-A in NEMCs; in contrast, FGF-2 but not hypoxia contributed to the enhanced VEGF-C expression, as shown in Fig. 3C . Neither hypoxia nor FGF-2 stimulated VEGF-C in BCEs (Fig. 3C) . Importantly, Northern blot analyses demonstrated that FGF-2-mediated upregulation of VEGF-C expression in NEMCs was relatively weak (approximately twofold) and transient, declining within 48 h (Fig. 3D) . Furthermore, FGF-2 did not affect PDGF-B expression in any of the cell types used (data not shown).
From these findings, it was difficult for us to conclude that FGF2 in vivo contributes directly to the marked enhancement of VEGF-C and PDGF-B expression in the later phase (day 7) in murine ischemic hindlimb with FGF-2 gene transfer.
Synergy Between VEGFR2 and VEGFR3 in ECs is Critical for PDGF-B Expression
We next focused on the possible relationship between VEGF-C and PDGF-BB. The mature form of human recombinant VEGF-C, a ligand for both VEGFR2/FLK-1 and VEGFR3/FLT-4 (22), stimulated PDGF-B expression of BCEs in a dose-dependent manner, as assessed by semiquantitative RT-PCR (Fig. 4A) , a finding also seen in HUVECs (data not shown). To determine which receptor was important for PDGF-BB expression, the VEGFR2/FLK-1-specific ligand VEGF-E (19) and the VEGFR3/FLT-4-specific ligand VEGF-C156S (10) were examined. As shown in Fig. 4B , these ligands synergistically upregulated the expression of PDGF-B mRNA (BCEs) and PDGF-BB protein (HUVECs), indicating that both VEGFR3 and VEGFR2 play critical roles in PDGF-BB expression via ECs. , lane 3) . VEGF-C expressed in the culture medium from these cells was only the secreted form, which binds only to VEGFR3/FLT-4 and not to VEGFR2/FLK-1, but not the mature form, which binds to both. The mature form of recombinant human VEGF-C (rhVEGF-C) was simultaneously examined as a positive control (lane 1). Note that the highly concentrated medium of HUVECs (20-fold, lane 2) was loaded. M, biotin-labeled molecular marker. C: FGF-2, but not hypoxia, upregulates VEGF-C gene expression in NEMCs, but not in ECs. After either 48 h [MRC5 and bovine aortic smooth muscle cells (BSMCs)] or 24 h [bovine capillary ECs (BCEs)] of precultivation under serum-free conditions with or without hypoxia (2% O2), the culture medium was replaced with fresh serum-free medium containing recombinant human FGF-2 (rhFGF-2; 10 ng/ml). Twenty-four hours later, cells were subjected to quantitative real-time RT-PCR analysis using species-specific primers and the TaqMan probe. Data were standardized by GAPDH gene expression in the same sample and were expressed as a fold increase over that in cells cultivated under normoxia without rhFGF-2. These cells were confirmed to express FGFR1 (data not shown). HUVECs were not included because of severe cell toxicity under such culture conditions. Values are means Ϯ SE; n ϭ 4 per group. *P Ͻ 0.01 and #P Ͻ 0.05. D: Northern blot analyses demonstrating that FGF-2 transiently stimulates VEGF-C gene expression in NEMCs from different species. At 48 h of precultivation under serum-free conditions, the culture medium was replaced with fresh serum-free medium containing rhFGF-2 (10 ng/ml). After 24 h, cells were harvested at each time point and subjected to Northern blot analysis. Quantitative data were analyzed by densitometry and expressed as a fold increase over that in cells at 0 h. Note that the effect of rhFGF-2 was transient in both cells. These experiments were done twice and showed similar results. bVEGF-C, bovine VEGF-C.
PDGF-BB Is a Strong Stimulator of VEGF-C in NEMCs
Next, we examined the possible inducer of VEGF-C in NEMCs with regard to the FGF-2/PDGF-BB axis. As shown in Fig. 5A , recombinant hFGF-2 mildly but significantly upregulated the secreted form of VEGF-C protein from human aortic smooth muscle cells, a finding that was markedly pronounced by recombinant human PDGF-BB (rhPDGF-BB) in a dose-dependent manner. This was also the case with MRC5 cells (data not shown). Neutralization of the antibody against PDGFR-␤, but not that against PDGFR-␣ significantly abrogated the rhPDGF-BB-mediated upregulation of VEGF-C expression (Fig. 5B) . In contrast, rhPDGF-BB had no effect on VEGF-C expression in HUVECs or BCEs without detectable PDGFR-␤ expression (data not shown). Together, these in vitro data, demonstrated in Figs. 4 and 5, suggest that a possible paracrine mode of action might stimulate ECs/PDGF-BB and NEMCs/VEGF-C (possibly involving VEGF-A) as a positive feedback system in the later phase following FGF-2 gene transfer.
The VEGF-C/PDGF-BB Axis Is a Positive Feedback System in Murine Severe Hindlimb Ischemia After FGF-2 Gene Transfer In Vivo
Finally, we determined whether or not the possible positive feedback system, VEGF-C/PDGF-BB, might play a role in the murine hindlimb ischemia model in vivo.
As shown in Fig. 6A , the blockade of endogenous activity of PDGF-BB via the administration of anti-PDGF-BB antibody completely abrogated the enhancement of endogenous mVEGF-C gene expression in the C57BL6/J limb salvage model mice on day 7 after FGF-2 gene transfer (Fig. 6A, left) . Inversely, the silencing of VEGFR3/FLT-4 activity by AFL-4 diminished the peak of mPDGF-B gene expression (Fig. 6A, right) . These results are clear evidence of the positive feedback loop of VEGF-C/ VEGFR3 and PDGF-BB.
In addition, we determined the biological role of endogenous PDGF-BB on FGF-2-mediated therapeutic neovascularization.
As shown in Fig. 6B , the administration of neutralizing antibody to PDGF-BB completely abolished the therapeutic effect of FGF-2 gene transfer on the Balb/c nu/nu autoamputation model, a finding similar to that seen in the use of AFL-4 (Fig. 1A) . This indicated that endogenous PDGF-BB activity contributes crucially to FGF-2-induced therapeutic neovascularization.
Taken together, the in vitro (Figs. 4 and 5) and in vivo (Fig.  6, A and B) data suggest that FGF-2-mediated angiogenesis/ lymphangiogenesis was determined by a positive feedback system of VEGF-C/VEGFR3 and PDGF-BB/PDGFR-␤, probably via a paracrine mode of action (Fig. 6C) .
DISCUSSION
Using mouse models of FGF-2-mediated therapeutic neovascularization, we here demonstrated that VEGF-C/VEGFR3 signaling, a well-known lymphangiogenic regulator, is a critical determinant of PDGF-BB-dependent capillary stabilization. The key observations in this study were as follows: 1) the blockade of VEGFR3/FLT-4 activity via AFL-4 completely abrogated the limb salvaging effect and the restoration of blood flow via FGF-2 (Fig. 1); 2) the administration of AFL-4 resulted in severe edema of ischemic hindlimb associated not only with diminished lymphangiogenesis, but also with disorganized capillary vessels (Figs. 1 and 2) ; 3) although VEGF-C and PDGF-B expression was upregulated 7 days after FGF-2 gene transfer, this effect was probably not a direct effect of FGF-2, because exogenous FGF-2 expression had already declined by that point (Fig. 3) ; 4) VEGF-C156S/VEGFR3 Fig. 4 . VEGF-C/VEGFR3 as a strong stimulator for PDGF-B gene and protein in ECs, and its synergy with VEGFR2 signaling. A: dose-dependent upregulation of PDGF-B gene expression on BCEs by rhVEGF-C (mature form stimulating both VEGFR2 and VEGFR3). At 24 h of precultivation with serum-free condition, the culture medium was replaced with serum-free fresh medium containing rhVEGF-C at various concentrations. Cells were harvested 24 h later and subjected to semiquantitative RT-PCR assessing gene expression of bovine PDGF-B gene (bPDGF-B). GAPDH gene expression was also examined as an internal control. This experiment was done twice and showed similar results. B: synergy of VEGFR2 and VEGFR3 signaling on PDGF-B gene and protein expression. At 48 h of precultivation under serum-free conditions, the culture medium was replaced with serum-free fresh medium containing rhVEGF-E (10 ng, specific for VEGFR2) and rhVEGF-C165S (10 ng, specific for VEGFR3). Cells were harvested 24 h later and subjected to quantitative real-time RT-PCR (left) or ELISA (right), assessing bPDGF-B or human PDGF-BB (hPDGF-BB), respectively. GAPDH gene expression was also examined as an internal control in BCEs (left). Values are means Ϯ SE; n ϭ 4 per group. *P Ͻ 0.01 and #P Ͻ 0.05. strongly stimulated PDGF-B gene and protein expression in the presence of VEGF-E/VEGFR2 signaling on ECs (Fig. 4) , and, inversely, PDGF-BB/PDGFR-␤ was crucial to VEGF-C expression on NEMCs in vitro (Fig. 5) ; and 5) the administration of anti-PDGF-BB antibody or AFL-4 completely abolished the enhanced expression of VEGF-C and that of PDGF-B in vivo, respectively (Fig. 6) .
To the best of our knowledge, this is the first report indicating that VEGF-C/VEGFR3 signaling contributes not only to lymphangiogenesis, but also to the later phase of the angiogenic process, specifically PDGF-BB-dependent capillary formation. Furthermore, the results suggest that angiogenesis and lymphangiogenesis are inseparable processes that significantly affect therapeutic angiogenesis.
One important issue that we came across during the study was whether the upregulation of VEGF-C and PDGF-B on day 7 in our model mice was a direct or indirect effect of exogenously boosted FGF-2, because we (Fig. 3) and others (13) have shown that FGF-2 could stimulate VEGF-C expression. Finally, we concluded that a direct effect of FGF-2 was not likely, for three reasons: 1) upregulation of VEGF-C and PDGF-B in vivo was found on day 7 after induced ischemia when expression of exogenous FGF-2 had already declined; 2) FGF-2-dependent VEGF-C expression was transient, occurring within 48 h, and far weaker than that seen by rhPDGF-BB in vitro; and 3) FGF-2-dependent PDGF-B expression was not found in any of the cell types tested. These findings suggested that some other stimulant(s) controls the expression of VEGF-C and PDGF-B. Thus we found a possible paracrine loop and tight communication between ECs and NEMCs in the use of VEGF-C and PDGF-BB around day 7 after induced ischemia (here called the maturation phase; please see Supplemental Fig. IV) .
Next, we have to explain how the early phase (here called the initiation phase) showing expression of exogenous FGF-2 would be followed by the maturation phase when FGF-2 expression has already declined. As we previously demonstrated, FGF-2 gene transfer strongly and synergistically enhanced endogenous VEGF-A expression under hypoxic conditions in vitro and in vivo (17, 25) ; in turn, the subsequent continuity of VEGF-A expression was determined by the PDGF-AA/PDGFR-␣/p70 S6K pathway, even when FGF-2 expression had returned to baseline (20, 28) . The latter system is important in the persistence of upregulation of VEGF-A expression on day 7 in this model (Refs. 20 and 28; Fig.  3 ). The present study suggests that continuous upregulation of VEGF-A may be a key to the subsequent positive feedback loop of VEGF-C/PDGF-BB, because VEGF-C/VEGFR3 signaling seemed necessary, although not sufficient, to induce PDGF-BB expression (Fig. 4) . Therefore, VEGF-A may play a crucial role in bridging from the initiation (FGF-2-dependent) to maturation (FGF-2-independent) phases (please see Supplemental Fig. IV) .
Although there is no doubt that the VEGF-C/VEGFR3 system is essential for inducing lymphangiogenesis (27, 29) , a number of conflicting findings regarding the lymphangiogenic Fig. 5 . PDGF-BB/PDGF receptor (PDGFR)-␤ as a strong stimulator for VEGF-C in NEMCs. A: expression of the secreted form of VEGF-C was more pronounced by recombinant human PDGF-BB (rhPDGF-BB) than by rhFGF-2, as assessed by Western blot analysis (left) and ELISA (right). The processes of cell culture and sample harvest were similar to those described in Fig. 3 . Similar data on bVEGF-C gene expression were obtained in the use of BSMCs (data not shown). Left: values are means Ϯ SE; each group contains n ϭ 4. *P Ͻ 0.01 and #P Ͻ 0.05. B: upregulation of VEGF-C was dependent on PDGFR-␤ but not on PDGFR-␣. The processes of cell culture and sample harvest were similar to those described in Fig. 3 . Values are means Ϯ SE; each group contains n ϭ 4. *P Ͻ 0.01. activity of VEGF-A have been reported by independent laboratories. For example, Kubo et al. (13) demonstrated that FGF-2, but not VEGF-A, induced lymphangiogenesis via a VEGF-C/VEGFR3-dependent mechanism in mouse cornea; however, other groups have shown that VEGF-A could stimulate not only angiogenesis, but also the proliferation of lymphatics in inflammatory foci (5), as well as in the tumor microenvironment (2) . Our present findings, specifically the synergistic effects of VEGF-A and VEGF-C on PDGF-BB expression (Fig. 4) , may well explain this paradox. That is, VEGF-A itself does not have lymphangiogenic activity without a significant amount of VEGF-C, such as in the case of a cornea pocket assay; however, VEGF-A can strongly stimulate PDGF-BB expression when endogenous VEGF-C is significantly upregulated by proinflammatory cytokines via a known mechanism (22) under conditions of inflammation and/or tumor proliferation. Subsequently, PDGF-BB also stimulates VEGF-C expression via a paracrine mode of action, as demonstrated in this study, possibly resulting in the marked enhancement of lymphangiogenesis. Direct PDGF-BB lymphangiogenic activity, which was shown to be independent of VEGF-C/VEGFR3, may also contribute to this process (3). However, a possible limitation of the present study that involves that the "paracrine mode of action" has been demonstrated using human and bovine cells, but not in murine cells in vitro that might be more relevant to the in vivo situations. Further studies, therefore, should be conducted to clarify such a complex angiogenesis/lymphangiogenesis network.
A deeply interesting finding obtained in this study was the area-specific increase of vasculature: angiogenesis was seen mostly in undamaged areas, whereas lymphangiogenesis was detected mainly in granulation tissue (Fig. 2B) . The blockade of VEGFR3/FLT-4 activity abolished lymphangiogenesis, but not angiogenesis, followed by severe limb edema and marked impairment of the recovery of blood flow. Even though the molecular and cellular mechanisms are largely unknown, this finding might provide an important insight into the injury repair process during tissue ischemia; the loss of lymphangiogenesis in the granulation tissue might result in the consumption of interstitial fluid, leading to edema. During this process, subsequent downregulation of PDGF-BB might be a cause of the disorganization of capillaries, even though their numbers increased in the proximal portion, further accelerating the tissue edema due to continuous hyperpermeability. This strongly suggests that lymphangiogenesis is absolutely necessary for therapeutic neovascularization. Further mechanistic investigations should be required to clarify this point.
In conclusion, the present study is the first to reveal the tight relationship between angiogenesis and lymphangiogenesis in the use of the positive feedback loop of VEGF-C/VEGFR3 and PDGF-BB/PDGFR-␤ via a possible paracrine mode of action. We believe that these findings may contribute to an understanding of the in vivo mechanisms of angiogenesis and to the development of more efficient therapeutic neovascularization.
